

For Immediate Release
For Further Information Contact:
Andrew Fisher at (301) 608-9292
Email: Afisher@unither.com

**REMODULIN[®] LONG-TERM DATA PRESENTED AT
AMERICAN HEART ASSOCIATION CONFERENCE**

Silver Spring, MD, November 10, 2003: United Therapeutics Corporation (NASDAQ: UTHR) announced today that data on the long-term efficacy and survival benefit of Remodulin were presented at the American Heart Association meeting in Orlando, Florida.

Jean-Luc Vachieri MD, cardiologist at the Free University and Erasme Hospital Brussels, Belgium, presented long-term data that showed persistent clinical improvements and prolonged survival in a cohort of 39 pulmonary arterial hypertension patients treated with Remodulin[®] for up to 54 months, with mean treatment time of 26 months. Dr. Vachieri reported that patients improved functional class by more than one of the four NYHA disease severity measurement units and their exercise tolerance improved by more than 150 meters during the study period.

“These data, together with very similar findings recently presented at other medical congresses, provide compelling evidence that Remodulin therapy confers long-term symptomatic and survival benefit to patients with pulmonary hypertension. Such data means that we will continue to use Remodulin as our preferred prostacyclin therapy for the treatment of PAH in the increasingly significant number of patients who fail oral therapy,” said Dr Vachieri.

Remodulin (treprostinil sodium) Injection is approved in the United States as a continuous subcutaneous infusion for the treatment of pulmonary arterial hypertension in patients with NYHA Class II-IV symptoms, to diminish symptoms associated with exercise. In clinical trials, the most common side effects reported with Remodulin therapy included infusion site pain (85%) and infusion site reaction (83%). Other adverse events included headache (27%), diarrhea (25%), nausea (22%), rash (14%), jaw pain (13%), vasodilatation (11%), dizziness (9%), edema (9%), pruritus (8%) and hypotension (4%). Remodulin should be used only by clinicians experienced in the diagnosis and treatment of pulmonary arterial hypertension.

United Therapeutics is a biotechnology company focused on combating chronic and life-threatening cardiovascular, infectious and oncological diseases with unique therapeutic products.